138 Hikma PHarmaceuticals Plc annual report 2011 notes to the consolidated financialstatements Continued 36. share-based payments Continued management incentive plan the 2009 management incentive Plan miP was approved by shareholders at the 2010 annual General meeting, whereby shareholders consented to the company satisfying awards under the miP from newly issued shares.
under the miP, the company makes grants of conditional awards to management across the Group below senior management level.
awards are dependent on the achievement of individual and Group kPis over one year and are then subject to a two year holding period.
the 2009 miP awards were made at the start of the kPi performance period, whereas the 2011 awards and future awards will be made at the end of the kPi performance period.
Details of the grants under the plan are shown below: 2011 grant 2009 grant 11 may 19 march total year 2011 number number number outstanding at 1 january 487,561 487,561 granted during the year 356,894 356,894 expired during the year 17,760 26,752 44,512 outstanding at 31 december 339,134 460,809 799,943 the cost of the management incentive plan of usD 2,415,000 2010: usD 615,000 has been recorded in the consolidated statement of comprehensive income as part of general and administrative expenses.
37. operating lease arrangements 2011 2010 $000 $000 minimum lease payments under operating leases recognised in the statement of comprehensive income for the year 4,368 3,514 at the balance sheet date, the Group had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows: 2011 2010 $000 $000 within one year 2,163 1,766 in the two to five years inclusive 3,345 4,159 5,508 5,925 Operating lease payments represent rentals payable by the Group for certain of its office properties.
leases are negotiated for a term of one to three years.
38. related party balances transactions between the company and its subsidiaries have been eliminated on consolidation and are not disclosed in this note.
transactions between the Group and its associate and other related parties are disclosed below.
trading transactions: During the year, Group companies entered into the following transactions with related parties: Darhold Limited: is a related party of the Group because it is considered one of the major shareholders of Hikma Pharmaceuticals Plc withownership percentage of 29.2% at the end of 2011 2010: 29.5%.
further details on the relationship between mr. samih Darwazah, mr. said Darwazah, mr. mazen Darwazah and mr. ali al-Husry, and Darhold limited are given in the Directors report.
Other than dividends as paid to all shareholders, there were no transactions between the Group and Darhold limited in the year.
